Ullem Scott B. 4

What Happened Scott B. Ullem, Chief Financial Officer of Edwards Lifesciences (EW), had performance-based restricted stock units convert into 19,830 shares on May 11, 2026. To satisfy tax withholding, 11,004 of those shares were disposed at $79.96 per share, generating $879,880. The filing shows the conversion/exercise of the performance rights and the subsequent tax-related share disposition.

Key Details

• Transaction date: May 11, 2026.
• Conversion/Vesting: 19,830 shares converted/issued (code M).
• Tax withholding/sale: 11,004 shares disposed at $79.96 for proceeds of $879,880 (code F).
• Origin of award: Performance-based restricted stock units granted May 11, 2023; Compensation Committee certified 167.70% of target vested as of May 11, 2026 (Footnote F1).
• Expiration: The related Performance Rights expire May 10, 2030 (Footnote F2).
• Shares owned after transaction: Not specified in this Form 4 (filing reflects only the change).
• Filing timeliness: Filing matches the report date (no late filing indicated).

Context This was primarily a vesting/conversion of performance-based awards, with a routine tax-withholding sale of a portion of the vested shares (cashless withholding). Such transactions reflect compensation vesting rather than an independent open-market sell signal.